Fatigue and Symptom Burden in Febrile Neutropenia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00503854|
Recruitment Status : Completed
First Posted : July 19, 2007
Last Update Posted : April 17, 2018
- To determine whether fatigue improves as patients are treated for febrile neutropenia (Day #1, Day #2 and Day #6).
- To identify clinical factors associated in cancer patients with low risk for outpatient treatment of febrile neutropenia on either outpatient febrile neutropenia treatment pathway presenting with moderate to severe fatigue. Moderate fatigue is defined as a score of 4 through 6 on the Brief Fatigue Inventory and severe fatigue is defined as a score of 7 through 10 on the Brief Fatigue Inventory.
- To describe demographic information in cancer patients with low risk for outpatient treatment of febrile neutropenia and fatigue while enrolled in either of two outpatient febrile neutropenia treatment pathways.
|Condition or disease||Intervention/treatment|
|Solid Tumors Febrile Neutropenia||Behavioral: Questionnaire|
|Study Type :||Observational|
|Actual Enrollment :||70 participants|
|Official Title:||Fatigue and Symptom Burden in Febrile Neutropenia|
|Actual Study Start Date :||May 31, 2007|
|Actual Primary Completion Date :||April 5, 2018|
|Actual Study Completion Date :||April 5, 2018|
|Fatigue and Fever Assessment||
Questionnaires taking about 15 to 30 minutes total.
Other Name: Survey
- Improvement in mean fatigue level from study day 1 to day 6 [ Time Frame: 6 Days (Baseline to Day 6) ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00503854
|United States, Texas|
|University of Texas MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Carmen Escalante, MD||M.D. Anderson Cancer Center|